{"title":"诱导化疗对局部晚期口腔鳞状细胞癌的作用。基于GRADE方法的系统综述和荟萃分析","authors":"Saisei Fu , Haruki Sato , Mitsuo Goto , Saki Tanno , Daisuke Takeda , Taiki Suzuki , Hidemichi Yuasa , Masatoshi Adachi , Narikazu Uzawa , Hiroshi Kurita","doi":"10.1016/j.ajoms.2023.08.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>A few reports have demonstrated the additional survival benefit obtained from induction chemotherapy. However, some facilities have differing opinions regarding the suitability of induction chemotherapy. The aim of this systematic review was to investigate the effectiveness of induction chemotherapy in patients with unresectable oral cancers without distant metastases.</p></div><div><h3>Methods</h3><p>A comprehensive search of randomized controlled trials was conducted specifically targeting patients with primary unresectable oral cancer, defined as an intervention group (induction chemotherapy followed by chemoradiotherapy) and a control group (chemoradiotherapy alone). The electronic databases PubMed, Cochrane Central Register of Controlled Trials, and Ichushi-Web database were searched for relevant papers. The primary outcome was overall survival, and the secondary outcomes were progression-free survival and treatment-related deaths, all of which were judged to be of critical importance. Data available for integration were subjected to a meta-analysis, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation approach.</p></div><div><h3>Results</h3><p>A search was conducted until February 2022, and four articles were included. The meta-analysis showed that the point estimates (95 % confidence interval) of the hazard ratios were 0.87 (0.74–1.01) for overall survival, 0.85 (0.75–0.97) for progression-free survival, and 0.98 (0.97–1.00) for treatment-related death. The certainty of the evidence for each item was very low.</p></div><div><h3>Conclusion</h3><p>Little data are available to support the use of induction chemotherapy before chemoradiotherapy in patients with unresectable primary locally advanced oral cancer.</p></div>","PeriodicalId":45034,"journal":{"name":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212555823002028/pdfft?md5=de670c5a03b4906e4905ee71a21a162d&pid=1-s2.0-S2212555823002028-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Role of induction chemotherapy for locally advanced oral squamous cell carcinoma. A systematic review and meta-analysis based on the GRADE approach\",\"authors\":\"Saisei Fu , Haruki Sato , Mitsuo Goto , Saki Tanno , Daisuke Takeda , Taiki Suzuki , Hidemichi Yuasa , Masatoshi Adachi , Narikazu Uzawa , Hiroshi Kurita\",\"doi\":\"10.1016/j.ajoms.2023.08.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>A few reports have demonstrated the additional survival benefit obtained from induction chemotherapy. However, some facilities have differing opinions regarding the suitability of induction chemotherapy. The aim of this systematic review was to investigate the effectiveness of induction chemotherapy in patients with unresectable oral cancers without distant metastases.</p></div><div><h3>Methods</h3><p>A comprehensive search of randomized controlled trials was conducted specifically targeting patients with primary unresectable oral cancer, defined as an intervention group (induction chemotherapy followed by chemoradiotherapy) and a control group (chemoradiotherapy alone). The electronic databases PubMed, Cochrane Central Register of Controlled Trials, and Ichushi-Web database were searched for relevant papers. The primary outcome was overall survival, and the secondary outcomes were progression-free survival and treatment-related deaths, all of which were judged to be of critical importance. Data available for integration were subjected to a meta-analysis, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation approach.</p></div><div><h3>Results</h3><p>A search was conducted until February 2022, and four articles were included. The meta-analysis showed that the point estimates (95 % confidence interval) of the hazard ratios were 0.87 (0.74–1.01) for overall survival, 0.85 (0.75–0.97) for progression-free survival, and 0.98 (0.97–1.00) for treatment-related death. The certainty of the evidence for each item was very low.</p></div><div><h3>Conclusion</h3><p>Little data are available to support the use of induction chemotherapy before chemoradiotherapy in patients with unresectable primary locally advanced oral cancer.</p></div>\",\"PeriodicalId\":45034,\"journal\":{\"name\":\"Journal of Oral and Maxillofacial Surgery Medicine and Pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2212555823002028/pdfft?md5=de670c5a03b4906e4905ee71a21a162d&pid=1-s2.0-S2212555823002028-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oral and Maxillofacial Surgery Medicine and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212555823002028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212555823002028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的 少数报告显示,诱导化疗可为患者带来额外的生存获益。然而,一些机构对诱导化疗的适用性持有不同意见。本系统综述旨在研究诱导化疗对无远处转移的不可切除口腔癌患者的有效性。方法对随机对照试验进行了全面检索,这些试验专门针对原发性不可切除口腔癌患者,分为干预组(诱导化疗后进行化放疗)和对照组(单纯化放疗)。研究人员在电子数据库 PubMed、Cochrane Central Register of Controlled Trials 和 Ichushi-Web 数据库中搜索了相关论文。主要结果是总生存期,次要结果是无进展生存期和治疗相关死亡,所有这些结果都被认为至关重要。对可用于整合的数据进行了荟萃分析,并采用建议分级评估、发展和评价方法对证据的确定性进行了评估。荟萃分析表明,总生存期的危险比点估计值(95% 置信区间)为 0.87(0.74-1.01),无进展生存期为 0.85(0.75-0.97),治疗相关死亡为 0.98(0.97-1.00)。结论对于无法切除的原发性局部晚期口腔癌患者,支持化疗前诱导化疗的数据很少。
Role of induction chemotherapy for locally advanced oral squamous cell carcinoma. A systematic review and meta-analysis based on the GRADE approach
Objective
A few reports have demonstrated the additional survival benefit obtained from induction chemotherapy. However, some facilities have differing opinions regarding the suitability of induction chemotherapy. The aim of this systematic review was to investigate the effectiveness of induction chemotherapy in patients with unresectable oral cancers without distant metastases.
Methods
A comprehensive search of randomized controlled trials was conducted specifically targeting patients with primary unresectable oral cancer, defined as an intervention group (induction chemotherapy followed by chemoradiotherapy) and a control group (chemoradiotherapy alone). The electronic databases PubMed, Cochrane Central Register of Controlled Trials, and Ichushi-Web database were searched for relevant papers. The primary outcome was overall survival, and the secondary outcomes were progression-free survival and treatment-related deaths, all of which were judged to be of critical importance. Data available for integration were subjected to a meta-analysis, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation approach.
Results
A search was conducted until February 2022, and four articles were included. The meta-analysis showed that the point estimates (95 % confidence interval) of the hazard ratios were 0.87 (0.74–1.01) for overall survival, 0.85 (0.75–0.97) for progression-free survival, and 0.98 (0.97–1.00) for treatment-related death. The certainty of the evidence for each item was very low.
Conclusion
Little data are available to support the use of induction chemotherapy before chemoradiotherapy in patients with unresectable primary locally advanced oral cancer.